• Sernova Biotherapeutics, Seraxis agreed to merge into BetaNova Biotherapeutics under a definitive deal signed Sept. 7, 2026.
• Companies closed a non-brokered convertible note financing into Seraxis totaling USD 11.2 million tied to the merger.
• On closing, Sernova, Seraxis shareholders expected to each hold about 50% of BetaNova on a non-diluted basis.
• Merger rationale centers on combining Seraxis’ stem cell-derived islet programs, cGMP manufacturing with Sernova’s Cell Pouch bio-hybrid organ platform.
• Financing proceeds earmarked for SR-02 manufacturing, a Phase 1/2 trial start in Q4, first dosing in Q1 2027, Nasdaq readiness in Q1 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sernova Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610050700PRIMZONEFULLFEED9839024) on October 05, 2026, and is solely responsible for the information contained therein.